Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The leading professional organisation for medical oncology
A week-long event presenting an overview of the scientific breakthroughs of 2021, with special emphasis on the presentation of Asian studies with the greatest impact on the science and practice of oncology.
Are you satisfied with the level of diversity, equity and inclusion in your workplace? Let us know.
Discover novel technologies in liquid biopsy for lung cancer and submit your questions to the experts in this live webinar
Reserved for registered users
Download the resources of this highly expected presentation in early breast cancer
Get recommendations for quality cancer care founded on the authoritative, evidence-based ESMO Guidelines and submit your questions to the experts
The best platform to share your lung cancer studies
Do not miss the opportunity! Submit your application by 25 October 2021
The ESMO-MCBS is a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
On the ESMO Perspectives, Elena Garralda discusses the latest achievements in precision oncology
It is indicated in patients who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy
Findings from the CheckMate 142 study in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer
Results of the ESMO Women for Oncology monitoring and authorship studies
The much-anticipated ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer has been published today in Annals of Oncology.
Updated results from the monarchE study point to abemaciclib benefit regardless of Ki-67 status
Findings from a phase I study of selective ROR1 targeting
Evidence for efficacy is based on the results from the KEYNOTE-826 study
New indication concerns the treatment of PD-L1 positive locally recurrent unresectable or metastatic TNBC
Statistical calibration allows for comparison of tumour mutational burden values across various panel assays
Sequencing data suggest that non-G12C KRAS mutations could mediate intrinsic resistance to treatments in non-small-cell lung cancer, but functional confirmation is required
AKT and EZH2 are identified as potential therapeutic targets to limit acquired resistance to osimertinib in patients with EGFR-mutated tumours of the lung
Molecular pre-screening identified targetable alterations in patients with unknown genomic drivers
Tumour-only molecular profiling can spot hereditary cancer syndromes but resources are critical to make the most of this piece of information
As the literature on exosomes continues to grow in cancer basic science, important questions remain regarding opportunities in the clinic
Inequities in access to targeted cancer treatments are due to the high costs of tests, limited number of approved medicines or clinical trials and poor communication with patients, as two new surveys report
Increased use of molecular profiling is progressively improving decision-making processes in oncology compared with 20 years ago and helping to shape tomorrow’s clinical trials in targeted therapies
Findings from international registries improve knowledge on how to manage cancer care in the pandemic era
Initial delays to antibody production are followed by similar levels of vaccine efficacy after a second vaccine dose
It is indicated in patients who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy
Findings from the CheckMate 142 study in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer
Updated results from the monarchE study point to abemaciclib benefit regardless of Ki-67 status
Findings from a phase I study of selective ROR1 targeting
Evidence for efficacy is based on the results from the KEYNOTE-826 study
New indication concerns the treatment of PD-L1 positive locally recurrent unresectable or metastatic TNBC
Statistical calibration allows for comparison of tumour mutational burden values across various panel assays
Third vaccine dose could be immunologically beneficial for patients on active chemotherapy
Integrated molecular-morphologic meningiomas classification by the German Consortium on Aggressive Meningiomas
Results of the ESMO Women for Oncology monitoring and authorship studies
The much-anticipated ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer has been published today in Annals of Oncology.
Data from early clinical trials presented at the ESMO Congress 2021 suggest that new anticancer treatments are on the horizon, with a clear emphasis on precision medicine.
First concrete results presented at the ESMO Congress 2021 confirm need to promote vaccination in patients with cancer
FIRSTMAPPP, the first randomised study in malignant pheochromocytoma and paraganglioma (MPP) has found that sunitinib prolongs progression-free survival (PFS) by more than five months
The PEACE-1 and STAMPEDE studies found that the addition of abiraterone acetate plus prednisolone (AAP) to standard therapy lengthened survival compared to standard therapy alone.
Adding a CDK 4/6 inhibitor to first-line hormonal treatment prolongs survival by one year for postmenopausal women with hormone receptor (HR) positive, HER2 negative advanced breast cancer, according to late breaking results of the MONALEESA-2 trial
The addition of immunotherapy to standard first-line treatment extends survival by eight months
The first randomised phase III clinical trial in stage II melanoma has shows a 35% reduction in the risk of recurrence with adjuvant pembrolizumab compared with placebo
ESMO has announced today the winners of the 2021 Society Awards.
Record Impact Factor increases for ESMO journals
ESMO Congress 2021: an enhanced virtual experience
Timely presentations of trial data will accelerate transition from research to practice
ESMO is pleased to offer members the opportunity to make a more active contribution to the development of the Society as we are looking to fill an important editorial position in one of our journals and for membership of two of our Working Groups.
Decide is the Health Decision Hub hosted by the World Health Organisation
ESMO has announced a collaboration with the WHO’s International Agency for Research on Cancer (IARC) to support them in the development of an online learning platform which integrates all research for cancer prevention in one easy-to-access point.
ESMO has taken the decision due to the uncertain evolution of the Coronavirus pandemic in the Asia-Pacific region and to avoid any risks to the health of the Faculty, delegates and staff.
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
Resources such as abstracts, presentations and webcasts from meetings can be accessed by ESMO members and conference delegates throughout all the year
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Switzerland
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
Take the CME test with E-learning and V-learning modules
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
